Sanofi India is a research-driven biopharma company that has been chasing the miracles of science in India for 70 years - and today it is essentially a diabetes powerhouse with a partnership model for everything else. It was incorporated in 1956 and spent decades building a broad prescription-drug franchise before a pivotal transformation in 2024-2025: it demerged its consumer healthcare business into a separate listed entity, then restructured its remaining general-medicine portfolio around its market-leading insulin franchise, handing its legacy cardiovascular, central-nervous-system and oral anti-diabetic brands to exclusive distribution partners while keeping brand ownership and manufacturing. The recurring approach is an “India-for-India” strategy - a focused, asset-light model that combines one world-class factory in Goa, a deep physician-trust moat built over decades, and a willingness to let specialist partners do the selling where the company no longer wants to deploy its own sales force.
Business segments
A single prescription-pharmaceuticals engine, split into two distinct go-to-market models - a diabetes franchise that the company sells and researches itself, and a portfolio of legacy brands that it owns and manufactures but distributes exclusively through partners.
1. Diabetes care: the insulin-led core that the company bets on
Sanofi India is the insulin market leader in India, and it is doubling down on this franchise with new drugs, digital tools, and patient-support programs while the addressable market races toward 157 million diabetics by 2050.
- Market leader in basal and premix insulin - the company holds a 31% market share in the combined basal and premix insulin segment, anchored by Lantus, which alone commands a 31% share in the basal category and ranks among the top 20 brands in the entire Indian pharmaceutical market.
- A full insulin toolkit, not just one drug - the portfolio spans Lantus (the basal workhorse), Toujeo (a second-generation basal insulin growing in double digits), Apidra (a rapid-acting analog that grew 13% in 2025), Soliqua (a once-daily insulin-plus-GLP-1 combination launched in 2024 that grew 90% in its first full year), and Insutage (a localized human insulin).
- Oral diabetes drugs complete the circle - Amaryl holds a 27% share in the Glimepiride market and Cetapin XR ranks sixth in Metformin, making Sanofi the only company with a substantial presence in both oral anti-diabetics and insulin in India.
- Patients stay on therapy because the company stays with them - the Saath 7 patient-support program, India’s longest-running such initiative, reaches over 100,000 patients annually through 90 certified counsellors across more than 45 cities, while a separate social-impact program provides free insulin and supplies to over 1,400 underprivileged children with Type 1 diabetes.
- The pipeline is built on real-world evidence - the LANDMARC study tracked close to 6,000 patients across 382 sites over three years, and a Phase IV study for Soliqua completed patient recruitment in December 2025, while Phase II and III trials are underway for Teplizumab, Brivekimig and Frexalimab.
2. Legacy pharmaceuticals: owned and made by Sanofi, sold by partners
Nine brands across cardiovascular, central-nervous-system and oral anti-diabetic therapies are now distributed and promoted exclusively by Emcure and Cipla under five-year agreements, while Sanofi retains brand ownership, manufacturing and import.
- Cardiovascular brands with decades of clinical trust - Cardace is the number-one ACE inhibitor by value with more than 29 years of Indian clinical experience, Clexane has been the standard of care in anticoagulation for over 25 years and was the first brand in India to cross ₹1,000 million, and Targocid leads the anti-MRSA category by value.
- The CNS franchise is built on India’s most-prescribed anticonvulsant - Frisium suspension is the number-one brand in the Clobazam market and the most prescribed brand across all anticonvulsants in India, with over 15 years of leadership.
- Partners buy at a fixed price and keep the upside - under all three agreements (CV with Emcure, CNS with Cipla, oral anti-diabetics with Emcure), the partner purchases product from Sanofi at a fixed price and can take any markup, so Sanofi gets a predictable manufacturing margin while the partner shoulders the selling cost and inventory risk.
Manufacturing and supply chain
One factory in Goa produces 5 billion tablets and capsules a year at a cost that beats the global top-quartile benchmark by 20%, and half of that output is exported.
- Cost-competitive at a global scale - the Goa site’s cost of USD 0.09 per unit in 2025 outperformed the top-quartile benchmark of USD 0.113 by 20%, and it has ranked as the third most cost-competitive solid-dosage plant globally among 35 Asian sites since 2017.
- Regulatory approvals open export doors - the site is overseen by more than a dozen health authorities including the USFDA, UK-MHRA, Health Canada, TGA Australia and WHO, which makes it a strategic sourcing hub for the Sanofi Group and the only facility besides Frankfurt authorised to produce Ramipril PC granules.
- Local contract manufacturing fills the gaps - the company works with seven Indian contract manufacturers, down from twelve, all qualified to the same quality and safety standards as the Goa site, and local production including these CMOs accounts for 24% of sales.
- The supply chain runs on closed-loop automation - highly automated systems minimise manual material handling, QR codes have replaced physical leaflets, and the site operates a zero-discharge policy with wastewater treated and reused for landscaping.
Group structure and partners
Sanofi India is a 60.4%-held, publicly listed subsidiary of the French parent Sanofi S.A., and it operates alongside a sister entity in India while its demerged consumer-healthcare business now trades as a separate listed company.
- Two entities, one group presence in India - Sanofi India Limited handles the prescription-pharma business described in this report, while Sanofi Healthcare India Private Limited (SHIPL) is a separate group company with which Sanofi India transacts for goods, services, toll manufacturing and product development; the group’s vaccines, specialty and clinical-studies businesses sit outside both entities.
- The consumer-healthcare business was demerged in 2024 - brands including Allegra, Combiflam, DePURA and Avil moved to Sanofi Consumer Healthcare India Limited, a separately listed company in which Sanofi also holds 60.4%, and shareholders received one SCHIL share for every Sanofi India share held.
- Exclusive partners now sell the legacy brands - Emcure Pharmaceuticals distributes and promotes the cardiovascular and oral anti-diabetic portfolios, while Cipla handles the CNS range, all under five-year agreements that leave brand ownership and manufacturing with Sanofi India.
- The global parent supplies the intellectual property - Sanofi-Aventis Singapore (SASPL) is the conduit for importing finished products and APIs and for exporting Indian-made goods, and it grants Sanofi India the exclusive right to use trademarks and IP free of cost for sale in India.